1-5 of 5
Abraham Lee
Close
Sort by
Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 3717.
https://doi.org/10.1182/blood-2023-177989
Published: 2023
Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 7257.
https://doi.org/10.1182/blood-2023-178771
Published: 2023
Journal Articles

Estimation of Postinfusion Resource Use and Total Costs of Care for Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 5084.
https://doi.org/10.1182/blood-2023-178761
Published: 2023
Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 2340.
https://doi.org/10.1182/blood-2023-178017
Published: 2023
Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Farrukh T. Awan, November McGarvey, Abraham Lee, Ken Imanak, Simran K. Tiwana, Sean Garrison, Masoom Priyadarshini
Journal: Blood
Blood (2023) 142 (Supplement 1): 7252.
https://doi.org/10.1182/blood-2023-178048
Published: 2023